AU2010353287A1 - Treatment of MCI and Alzheimer's disease - Google Patents

Treatment of MCI and Alzheimer's disease Download PDF

Info

Publication number
AU2010353287A1
AU2010353287A1 AU2010353287A AU2010353287A AU2010353287A1 AU 2010353287 A1 AU2010353287 A1 AU 2010353287A1 AU 2010353287 A AU2010353287 A AU 2010353287A AU 2010353287 A AU2010353287 A AU 2010353287A AU 2010353287 A1 AU2010353287 A1 AU 2010353287A1
Authority
AU
Australia
Prior art keywords
nifedipine
pharmaceutical composition
nitroso
lactam
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010353287A
Other languages
English (en)
Inventor
Mark Lovell
Bert Lynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
Original Assignee
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/034721 external-priority patent/WO2010132671A1/en
Application filed by University of Kentucky Research Foundation filed Critical University of Kentucky Research Foundation
Publication of AU2010353287A1 publication Critical patent/AU2010353287A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2010353287A 2010-05-13 2010-11-18 Treatment of MCI and Alzheimer's disease Abandoned AU2010353287A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2010/034721 WO2010132671A1 (en) 2009-05-15 2010-05-13 Treatment of mci and alzheimer's disease
AUPCT/US2010/034721 2010-05-13
PCT/US2010/057287 WO2011142778A1 (en) 2010-05-13 2010-11-18 Treatment of mci and alzheimer's disease

Publications (1)

Publication Number Publication Date
AU2010353287A1 true AU2010353287A1 (en) 2012-11-29

Family

ID=44923820

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010353287A Abandoned AU2010353287A1 (en) 2010-05-13 2010-11-18 Treatment of MCI and Alzheimer's disease

Country Status (6)

Country Link
EP (1) EP2568811A4 (https=)
JP (1) JP2013526518A (https=)
CN (1) CN102984938A (https=)
AU (1) AU2010353287A1 (https=)
CA (1) CA2799162A1 (https=)
WO (1) WO2011142778A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044737T2 (hu) * 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
SG11201510701QA (en) 2013-06-28 2016-01-28 Mcbi Inc Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
ES2693771T3 (es) * 2014-01-29 2018-12-13 Bristol-Myers Squibb Company Inhibidores de aril lactama quinasa
CN106177046A (zh) * 2016-08-29 2016-12-07 杨添福 一种基于普立宁钾开发的神经认知障碍治疗药物及其制备方法
CN106645505A (zh) * 2016-11-18 2017-05-10 中国医科大学 可实现glt‑1蛋白鉴定及绝对定量的试剂盒及测定方法
CN107022019B (zh) * 2016-11-24 2020-10-30 桂林医学院 一种用于脑内降铁除自由基的多肽、制备方法与应用
CN106636388A (zh) * 2016-12-15 2017-05-10 湖南中能荆卫生物科技有限公司 用于亨廷顿病诊断的基因及其应用以及由其编码的蛋白和蛋白的应用
CN108191966B (zh) * 2018-01-11 2020-10-27 桂林医学院 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽
AU2020207203A1 (en) * 2019-01-07 2021-08-19 Cenna Biosciences Inc. Novel peptides and uses thereof
JP7321017B2 (ja) * 2019-07-17 2023-08-04 東海物産株式会社 機能性食品

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8002A (en) * 1851-03-25 Upright pianoforte
DE2126533A1 (de) * 1971-05-28 1972-12-14 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur Herstellung pharma zeutischer Zubereitungen
CA2325353A1 (en) * 1998-04-08 1999-10-14 Oregon Health Sciences University Enhancement of cellular gallium uptake
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
WO2002041893A1 (en) * 2000-11-21 2002-05-30 Howard Zik Therapy for herpes neurological viral conditions utilizing 1,4-dihydropyridine calcium channel blockers
CA2546395A1 (en) * 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors
PT1874311E (pt) * 2005-04-15 2011-11-25 Res & Innovation S P A Método para prevenir, retardar ou reverter a deposição anómala de amilóide
EP1955698B1 (en) * 2005-12-02 2013-10-30 Mochida Pharmaceutical Co., Ltd. Preventive/therapeutic agent for alzheimer's dementia
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
WO2008051291A2 (en) * 2006-04-11 2008-05-02 Ordway Research Institute Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
WO2008109613A1 (en) * 2007-03-05 2008-09-12 Wyeth Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors
WO2010034110A1 (en) * 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
TW201103907A (en) * 2009-03-20 2011-02-01 Lundbeck & Co As H Amide derivatives as neuropeptide Y5 receptor ligands

Also Published As

Publication number Publication date
EP2568811A4 (en) 2014-03-12
CN102984938A (zh) 2013-03-20
EP2568811A1 (en) 2013-03-20
CA2799162A1 (en) 2011-11-17
WO2011142778A1 (en) 2011-11-17
JP2013526518A (ja) 2013-06-24

Similar Documents

Publication Publication Date Title
AU2010353287A1 (en) Treatment of MCI and Alzheimer's disease
US20100292281A1 (en) Treatment of mci and alzheimer's disease
US9968574B2 (en) Treatment of MCI and Alzheimer's disease
CA2722295C (en) Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
AU2013334874B2 (en) Combination therapies for the treatment of Alzheimer's disease and related disorders
Fernandez‐Perez et al. Synaptic dysregulation and hyperexcitability induced by intracellular amyloid beta oligomers
WO2013032351A1 (en) Treatments involving eslicarbazepine acetate or eslicarbazepine
EP2219649A2 (en) Use of mnk inhibitors for the treatment of alzheimer's disease
JP2016521755A (ja) 代謝障害を治療するための組成物および方法
WO2011050095A2 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)
AU2017383127B2 (en) Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
Sose et al. An Update on Autophagy as a Target in the Treatment of Alzheimer’s Disease
US20100247688A1 (en) Pirenzepine and derivatives thereof as anti-amyloid agents
KR101173677B1 (ko) Ｅｐｐｓ를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물
Lovell et al. Treatment of MCI and Alzheimer's Disease
EP2462131B1 (en) Compositions and methods for treating beta-amyloid related diseases
AU2023347307A1 (en) Methods of reducing neurodegeneration associated with neurodegenerative diseases
ES2449594T3 (es) Método para reducir deposición amiloide, neurotoxicidad amiloide y microgliosis con enantiomero (-)-nilvadipina
EP4725482A1 (en) Glucokinase activator for cognitive disorders and neurodegenerative diseases
Ranade et al. TARGET EVOLUTION AND THERAPY ADVANCEMENTS FOR ALZHEIMER’S DISEASE: A REVIEW
TW202438074A (zh) 噁二唑衍生物化合物及包含其之醫藥組合物
KR20130030011A (ko) 뇌손상에 의한 전두엽 기능장애 모델 동물 및 전두엽 기능장애의 개선용 조성물

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period